← board
ADXN
distress 3/10 · well-funded / low risk$5.880%today-46% from 52w high
Revenue
pre-revenue
Liquidity
$4M
Runway
1.8 yrs
Shares 1y
0%
Price & events
-26.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.2%
1D
-4.9%
1W
-9.7%
1M
-10.8%
3M
-26.4%
6M
-24.8%
1Y
-27.0%
2Y
-96.9%
5Y
-97.9%
All
Overview
- Market Cap
- $869.99M
- Volume
- 200
- 52 Week Range
- $5.60 – $10.95
- Total Shares
- 147.83M
- Float Shares
- 808.87K
- Short %
- 0.14%
- % Held by Insiders
- 0.00%
- % Held by Institutions
- 0.04%
- RVOL
- 0.05x
- Beta
- 1.99
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2024-07-31HC Wainwright & Co.Neutral → Buy
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.